title: [Basic and clinical studies of pazufloxacin on infectious enteritis research group of T-3761 on infectious enteritis].
abstract: A clinical study was carried out on pazufloxacin (PZFX) in 137 patients including shigellosis, Salmonella enteritis, enteropathogenic Esherichia coli enteritis and cholera, and carriers of these pathogens. Antibacterial activity of PZFX against clinical isolates, fecal concentration of PZFX and effects of PZFX on fecal microflora were also investigated. The overall clinical efficacy rate was 97.2%. The bacteriological efficacy rates were 98.2% against Shigella spp., 81.8% against Salmonella spp., 50% against Vibrio cholerae O1, and 100% against E. coli, V. parahaemolyticus, Aeronomas spp., Plesionomas shigelloides and V. cholerae non-O1, respectively. Side effect (epigastralgia) was observed in 1 of 130 cases (0.8%). The rate of abnormal laboratory findings was 11.2% (11/98). These were mainly elevation of GOT and/or GPT and increased eosinophils. The clinical usefulness rate was 95.2%. The MIC90 values of PZFX against Shigella spp., Salmonella spp. and E. coli were 0.025, 0.025 and 0.025 micrograms/ml, respectively. The results of fecal drug concentration and the effects on fecal microflora in one patient were compatible with those obtained in healthy volunteers.
authors.affiliation: Department of Infectious Diseases, Yokohama Municipal Citizen's Hospital.
authors.forename: H
authors.initials: H
authors.lastname: Sagara
authors.forename: K
authors.initials: K
authors.lastname: Yoshikawa
authors.forename: I
authors.initials: I
authors.lastname: Tomizawa
authors.forename: Y
authors.initials: Y
authors.lastname: Takizawa
authors.forename: Y
authors.initials: Y
authors.lastname: Nitta
authors.forename: T
authors.initials: T
authors.lastname: Tsunoda
authors.forename: H
authors.initials: H
authors.lastname: Fukuda
authors.forename: T
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: G
authors.initials: G
authors.lastname: Masuda
authors.forename: M
authors.initials: M
authors.lastname: Negishi
authors.forename: A
authors.initials: A
authors.lastname: Ajisawa
authors.forename: M
authors.initials: M
authors.lastname: Murata
authors.forename: K
authors.initials: K
authors.lastname: Ohnishi
authors.forename: S
authors.initials: S
authors.lastname: Irimajiri
authors.forename: M
authors.initials: M
authors.lastname: Obana
authors.forename: F
authors.initials: F
authors.lastname: Matsumoto
authors.forename: T
authors.initials: T
authors.lastname: Imai
authors.forename: I
authors.initials: I
authors.lastname: Sakurai
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
authors.forename: M
authors.initials: M
authors.lastname: Mori
authors.forename: Y
authors.initials: Y
authors.lastname: Mizuno
authors.forename: K
authors.initials: K
authors.lastname: Katoh
authors.forename: S
authors.initials: S
authors.lastname: Hosoda
authors.forename: T
authors.initials: T
authors.lastname: Bamba
authors.forename: M
authors.initials: M
authors.lastname: Saito
mesh_terms: D042462:4-Quinolones; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology*; D002353:Carrier State / Q000188:drug therapy; D002771:Cholera / Q000188:drug therapy / Q000382:microbiology; D004352:Drug Resistance, Microbial; D004405:Dysentery, Bacillary / Q000188:drug therapy / Q000382:microbiology; D004751:Enteritis / Q000188:drug therapy* / Q000382:microbiology*; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000382:microbiology; D024841:Fluoroquinolones; D006801:Humans; D010078:Oxazines / Q000494:pharmacology / Q000627:therapeutic use*; D012480:Salmonella Infections / Q000188:drug therapy / Q000382:microbiology
chemical_list: D042462:4-Quinolones; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D010078:Oxazines; C078052:pazufloxacin